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Abstract (current word count: 200) 
The long-term safety, tolerability and efficacy of high-dose 13.3 mg/24 h rivastigmine 
patch in severe Alzheimer’s disease was evaluated in a 24-week, open-label extension 
to the double-blind (DB) ACTION study. Safety and tolerability, and efficacy on the 
Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale–Severe 
Impairment Version (ADCS-ADL-SIV), Severe Impairment Battery (SIB), and ADCS–
Clinical Global Impression of Change (ADCS-CGIC) were assessed. Overall, 197 
patients continued on 13.3 mg/24 h patch; 199 up-titrated from 4.6 mg/24 h to 13.3 
mg/24 h patch. The incidence of adverse events (AEs), serious AEs and 
discontinuations due to AEs was similar in patients who continued on, and patients who 
up-titrated to, 13.3 mg/24 h patch (AEs: 57.9% and 59.8%; serious AEs: 16.2% and 
16.1%; discontinuations: 11.2% and 12.1%, respectively). Larger mean changes from 
DB baseline were observed in patients up-titrated on the ADCS-ADL-SIV (−4.6 
[standard deviation 8.7]) and SIB (−7.0 [16.6]), than those who continued on 13.3 
mg/24 h patch (−3.9 [8.0] and −4.7 [16.8], respectively). ADCS-CGIC scores were 
comparable. There were no clinically relevant between-group differences in safety and 
tolerability. Greater decline was observed in patients with delayed up-titration to high-
dose 13.3 mg/24 h patch than patients who continued on high-dose patch.  
 
Key words: severe Alzheimer’s disease, rivastigmine, transdermal patch, open-label 
clinical trial 
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Introduction 
Alzheimer’s disease (AD) is a neurodegenerative illness and the most common cause 
of dementia.1 As the disease progresses, patients experience degeneration of cortically 
projecting cholinergic neurons,2 resulting in progressive impairments in cognition, 
particularly memory, behavior, and performance of activities of daily living (ADL).1 
Cholinesterase inhibitors (ChEIs) are the mainstay of treatment and provide 
symptomatic benefits by partially compensating for the cholinergic deficits associated 
with AD.2 In the absence of disease-modifying therapies, there remains a need to 
optimize use of available therapies at all stages of AD. 
Currently, several agents are approved in the USA to manage patients with AD. Three 
ChEIs are indicated for the treatment of mild-to-moderate AD: rivastigmine (Exelon®, 
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA), donepezil (Aricept®, 
Eisai Inc., Woodcliff Lakes, NJ, USA), and galantamine (Razadyne®, Janssen 
Pharmaceutical NV, Beerse, Belgium).3-6 Donepezil and an N-methyl-D-aspartate 
receptor antagonist (memantine [Namenda XR™], Forest Pharmaceuticals Inc., St 
Louis, MO, USA) are indicated for the treatment of severe AD.3, 7 Rivastigmine is 
currently the only approved treatment for AD available in both oral and transdermal 
formulations.4, 5 The transdermal system was initially indicated for the treatment of mild-
to-moderate AD at rivastigmine dosages of 4.6 mg/24 h and 9.5 mg/24 h.5 A 13.3 
mg/24 h dosage strength was later approved based on data from the OPTIMA 
(OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer’s disease) study, 
described elsewhere.8  
In June 2013, the US Food and Drug Administration approved an expanded indication 
for the 13.3 mg/24 h rivastigmine transdermal system to include the symptomatic 
treatment of patients with severe AD.5 Approval was based on the ACTION (ACTivities 
of Daily Living and CognitION in Patients with Severe Dementia of the Alzheimer's 
Type) study, a 24-week, randomized, double-blind (DB) study that compared the 
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efficacy, safety and tolerability of rivastigmine 13.3 mg/24 h patch with 4.6 mg/24 h 
patch in patients with severe AD.9, 10 The 13.3 mg/24 h patch demonstrated statistically 
significantly (P < 0.05) less decline in overall cognition and function in patients with 
severe AD at Week 24, as assessed using the Severe Impairment Battery (SIB) and 
the Alzheimer’s Disease Cooperative Study–ADL scale–Severe Impairment Version 
(ADCS-ADL-SIV), respectively (co-primary outcomes).9 A similar proportion of both 
treatment groups (13.3 mg/24 h and 4.6 mg/24 h patch) reported adverse events (AEs; 
74.6% and 73.3%, respectively) and serious AEs (SAEs; 14.9% and 13.6%, 
respectively).9  
In the current manuscript, we present the main findings of an open-label extension 
(OLE) to the DB ACTION study. This extension study was designed to investigate the 
effects of 13.3 mg/24 h rivastigmine patch over a longer term with regards to safety and 
clinical outcomes in patients with severe AD. These data have previously been 
presented in poster form at the Alzheimer’s Association International Conference, 
Boston, MA, USA, July 13–18 2013,11 the American College of Clinical Pharmacology 
Annual Meeting, Bethesda, MD, USA,12 September 22–24 2013, and the World 
Congress of Neurology, Vienna, Austria, September 21–26 2013.13 
 
Methods  
Patients and Study Design  
The methodology for the ACTION study has been previously described,9, 10 and the 
clinical study is registered (ClinicalTrials.gov Identifier: NCT00948766). The protocol 
and amendments were reviewed by Independent Ethics Committees or Institutional 
Review Boards and the study was conducted in accordance with Good Clinical Practice 
and the ethical principles of the Declaration of Helsinki. All patients, or if they lacked 
capacity, their legally authorized representative, provided written informed consent 
before participating in the DB study and OLE.  
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Patients enrolled in the DB study were male and female, aged ≥50 years with a clinical 
diagnosis of AD, according to the National Institute of Neurological and Communicative 
Disorders and Stroke and the AD and Related Disorders Association 
[NINCDS/ADRDA] criteria.14 In addition, patients were required to score between 3–12 
(inclusive; severe AD) on the Mini-Mental State Examination at DB baseline.15 The 
brain scan (magnetic resonance imaging or computed tomography) used for 
establishing the NINCDS/ADRDA criteria must have been performed within 2 years 
prior to the baseline visit.  
Patients were excluded from the DB study if they had any advanced, severe, 
progressive, or unstable disease that could interfere with the efficacy and safety 
assessments; were currently residing or likely to be placed in a nursing home within the 
next 7 months; or had any medical or neurological conditions other than AD that could 
be the primary cause of dementia. Additional exclusion criteria for the DB study have 
been previously described.9, 10  
Patients who completed the 24-week, prospective, randomized, parallel-group, DB, 
multicenter ACTION study were eligible to continue in an open-label, forced-titration, 
24-week extension. Patients continuing in the OLE were required to have met all 
inclusion (and no exclusion) criteria at DB baseline. There was a continued 
requirement for patients to be residing with someone in the community or be in regular 
contact with the primary caregiver; and have a primary caregiver willing to accept 
responsibility for supervising treatment. In addition, patients were required 
(investigator’s opinion) to be medically stable and tolerating their current dose of 
rivastigmine patch. 
At the end of the DB study (Week 24) patients who chose to participate in the OLE 
were switched from DB treatment with rivastigmine 13.3 mg/24 h or 4.6 mg/24 h patch 
to open-label treatment with rivastigmine 9.5 mg/24 h patch. Patients remained blind to 
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treatment assignment in the core study. After 4 weeks on the maintenance dose (9.5 
mg/24 h patch), patients continued on open-label treatment with the higher-dose 
rivastigmine 13.3 mg/24 h patch for an additional 20 weeks (Weeks 28–48). 
Dose adjustments and interruptions were permitted for patients who were not able to 
tolerate the specified dosing regimen. If a patient experienced a problem with 
tolerability, the patch was removed, and 1 or 2 days of no treatment were permitted. 
Tolerability was reassessed after the 1- or 2-day period. If tolerability had improved and 
there were no more than 3 consecutive days of interruption, treatment was reinstated 
at the same dosage. If tolerability was not improved after 3 consecutive days or if 
treatment was interrupted for more than 3 consecutive days, treatment was reinitiated 
at the 4.6 mg/24 h patch dose. After a minimum of 2 weeks, the dose could be titrated 
up to 9.5 mg/24 h patch and again after a minimum of 2 weeks up to 13.3 mg/24 h 
patch. If the intolerability persisted, the patient was discontinued from the study. 
Study Objectives 
The primary objective of this OLE of the 24-week DB ACTION study was to investigate 
the long-term safety of rivastigmine 13.3 mg/24 h patch in patients with severe AD. 
Secondary objectives were to investigate the long-term efficacy of rivastigmine 13.3 
mg/24 h patch in this patient population. 
Outcomes  
Safety and tolerability was assessed throughout the study and included reporting of the 
incidence of AEs, SAEs, and the rate of discontinuation due to AEs and SAEs. Safety 
assessments included regular monitoring of vital signs, physical condition, and body 
weight. Laboratory tests, electrocardiogram, and physical examination were performed 
at Week 48 or when the patient withdrew or discontinued the study.  
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Efficacy was assessed by calculating the mean change from DB baseline to Week 48 
on the ADCS-ADL-SIV and SIB, and the Week 48 score on the ADCS–Clinical Global 
Impression of Change (ADCS-CGIC).16-18 
Statistical Analysis  
Analysis of the primary outcome (long-term safety) was based on the safety set for the 
OLE and included all patients who received at least one dose of rivastigmine patch and 
had at least one safety assessment during the OLE. The incidence of AEs and SAEs 
and discontinuation due to AEs and SAEs was summarized by primary system organ 
class and preferred term. The relationship of the observed AE to study drug, action 
taken, duration and severity were also recorded. For laboratory evaluations and vital 
signs, the change from baseline and proportion of patients experiencing clinically 
notable laboratory evaluations were calculated. 
 
Analyses of the secondary outcomes (long-term efficacy variables [ADCS-ADL-SIV, 
SIB and ADCS-CGIC]) were based on the modified full analysis set (MFAS) for the 
OLE. The MFAS comprised all patients who received at least one dose of rivastigmine 
patch and had at least one efficacy assessment during the OLE. Imputation of missing 
values was performed following the last-observation-carried-forward (LOCF) approach. 
Data from the DB study were not carried forward for the efficacy summary from the 
open-label study. Data were analyzed according to treatment group in the randomized, 
DB treatment phase (rivastigmine 13.3 mg/24 h or 4.6 mg/24 h patch). Additional 
supportive analyses (observed case [OC]) were performed to confirm whether 
imputations influenced the results.   
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For continuous efficacy and safety variables, number of patients with observed values 
(n), mean, standard deviation (SD), 95% confidence intervals, minimum and maximum 
values were calculated. Categorical efficacy and safety variables were summarized by 
frequency counts and percentages. Unless otherwise specified, all statistical tests were 
conducted against a 2-sided alternative hypothesis; P-values below 0.05 were 
considered significant. 
Results 
Participants  
Of the 463 patients who completed the DB study, 396 patients entered the OLE and 
received rivastigmine patch: 197 continued on the rivastigmine 13.3 mg/24 h patch; 
199 were switched from the rivastigmine 4.6 mg/24 h patch to the 13.3 mg/24 h patch. 
A similar proportion of both groups completed the OLE (76.8% [n = 152] for 13.3 mg/24 
h patch and 77.4% [n = 154] for the group originally randomized to 4.6 mg/24 h patch 
in the DB phase; Figure 1).  
Overall, AEs (based on DB treatment allocation, 9.6% [n = 19] for 13.3 mg/24 h patch 
and 12.1% [n = 24] for 4.6 mg/24 h patch) and consent withdrawal (8.1% and 8.0%, 
respectively [n = 16 for both groups]; Figure 1) were the most commonly reported 
reasons for discontinuation. No imbalance was observed between treatment groups. 
Generally, baseline demographics and characteristics were comparable between the 
rivastigmine 13.3 mg/24 h and 4.6 mg/24 h patch groups (Table 1). 
Safety and Tolerability  
The mean duration of exposure to rivastigmine during the OLE was comparable 
between patients who received 13.3 mg/24 h patch and those who received 4.6 mg/24 
h patch in the DB phase; the mean duration was 21.7 weeks for patients who continued 
treatment with 13.3 mg/24 h patch and 21.2 weeks for those who switched to the high-
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dose patch. When exposure to rivastigmine during the DB study was included, the 
mean duration was 46.3 weeks and 45.8 weeks, respectively.  
No new safety findings from long-term treatment with the rivastigmine patch were seen 
based on the incidence of individual AEs or SAEs, individual AEs resulting in 
discontinuation, laboratory or electrocardiogram results, or vital signs.  
Overall, there was a comparable incidence of AEs between patients who continued on 
rivastigmine 13.3 mg/24 h patch (57.9%) and those switched from 4.6 mg/24 h patch 
(59.8%; Table 2). The most commonly reported AEs (≥10% in either group) with 
13.3 mg/24 h rivastigmine patch (DB 13.3 mg/24 h and 4.6 mg/24 h, respectively) 
defined by primary system organ class were: infections and infestations (18.8% and 
18.1%); psychiatric disorders (14.2% and 19.1%); gastrointestinal (GI) disorders 
(13.2% and 16.6%); nervous system disorders (14.2% and 13.6%); investigations (e.g. 
procedures, abnormal laboratory results; 13.2% and 13.1%); general disorders and 
administration site conditions (10.7% and 11.6%); and injury, poisoning, and procedural 
complications (10.2% and 8.5%). By preferred term, patients who continued on 
rivastigmine 13.3 mg/24 h patch reported fewer incidences of vomiting, fall, agitation, 
and diarrhea compared with those randomized to receive rivastigmine 4.6 mg/24 h 
patch in the DB phase; the converse was observed with regard to the incidence of 
urinary tract infection (Table 2). Application site erythema and dermatitis were 
experienced by a similar percentage of patients in both groups (based on DB treatment 
allocation, 13.3 mg/24 h patch: 1.5% and 2.0%, respectively; 4.6 mg/24 h patch: 2.0% 
for each). The majority of reported AEs were mild or moderate in severity. AEs of mild 
severity were experienced by 26.4% of patients who continued on 13.3 mg/24 h patch 
and 27.6% of patients who switched from 4.6 mg/24 h patch (moderate: 20.8% and 
23.1%, respectively; severe: 10.7% and 9.0%, respectively).   
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During the OLE, a comparable incidence of SAEs was observed in those patients who 
continued on (16.2%) and those switched to (16.1%) 13.3 mg/24 h patch (Table 3), 
with nervous system disorders the most commonly reported (6.6% and 4.5%, 
respectively). A numerically higher incidence of discontinuation due to SAEs was 
observed in those patients continued on the 13.3 mg/24 h patch (7.1% [n = 14]) 
compared with those switched from the 4.6 mg/24 h patch (5.0% [n = 10]) (Table 3). 
Conversely, discontinuations due to non-serious AEs were numerically higher for those 
patients switched from the 4.6 mg/24 h patch (7.5% [n = 15]) compared with those 
continued on the 13.3 mg/24 h patch (4.6% [n = 9]) (Table 3). 
Four (2.0%) deaths were reported for patients who continued on the 13.3 mg/24 h 
patch (Table 3); none of these deaths were suspected to be related to the study drug. 
Two of the four deaths were related to cardiac events, one was due to dementia related 
to AD, and one was due to chemical poisoning. No deaths were reported for patients 
switched from 4.6 mg/24 h to 13.3 mg/24 h patch. 
Efficacy Outcomes 
SIB  
During the DB study, patients treated with the rivastigmine 13.3 mg/24 h patch 
demonstrated significantly less decline on the SIB at Week 24, compared with those 
treated with the 4.6 mg/24 h patch (P < 0.0001).9 During the OLE, both groups 
demonstrated clinical decline. A larger mean (SD) change from DB baseline at Week 
48 in SIB total score was observed in those patients switched from rivastigmine 4.6 
mg/24 h patch at the start of the OLE (−7.0 [16.6], P < 0.0001 for change from DB 
baseline) than for those continued on rivastigmine 13.3 mg/24 h patch throughout (−4.7 
[16.8], P = 0.0002 for change from DB baseline; Figure 2A), indicating less decline 
among patients continued on the 13.3 mg/24 h patch relative to those switched from 
4.6 mg/24 h patch. Results were similar for the MFAS-OC population. 
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ADCS-ADL-SIV 
During the overall 48-week period, decline in functional performance (as measured by 
the ADCS-ADL-SIV) was observed in both rivastigmine patch groups. During the DB 
study, patients treated with the 13.3 mg/24 h patch had significantly less decline on the 
ADCS-ADL-SIV at Week 24 compared with the 4.6 mg/24 h patch (P = 0.025).9 During 
the OLE, patients switched from rivastigmine 4.6 mg/24 h patch (−4.6 [8.7], P < 0.0001 
for change from DB baseline) showed a larger mean (SD) change from DB baseline at 
Week 48 compared with those patients who continued on the 13.3 mg/24 h patch (−3.9 
[8.0], P < 0.0001 for change from DB baseline; Figure 2B) indicating less decline 
among patients continued on the 13.3 mg/24 h patch relative to those switched from 
the 4.6 mg/24 h patch. Results were similar for the MFAS-OC population. 
ADCS-CGIC  
A similar percentage of patients in both rivastigmine patch groups improved, worsened, 
or showed no change in ADCS-CGIC ratings (Figure 2C). At Week 48, 16.5% of all 
patients showed improvement in mental/cognitive state, behavior, and functioning. No 
change in ADCS-CGIC ratings was seen in 26.2% of all patients and 57.2% showed 
minimal to marked worsening of their medical condition.  
Discussion 
Overall, no new safety or tolerability issues were reported during this 24-week OLE to 
the DB ACTION study, in patients with severe AD. The overall incidence of AEs was 
comparable between patients who continued on 13.3 mg/24 h rivastigmine patch 
throughout the DB study and OLE, and those who up-titrated from 4.6 mg/24 h to 13.3 
mg/24 h patch at the start of the OLE (57.9% versus 59.8%). The core 24-week, DB 
ACTION study also reported a similar incidence of AEs between patients randomized 
to 4.6 mg/24 h or 13.3 mg/24 h patch (73.3% and 74.6%, respectively).9  
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Discontinuations due to skin irritation were few in the DB phase of the study (1.7% 
versus 2.5%, 13.3 mg/24 h and 4.6 mg/24 h rivastigmine patch, respectively; 2.1% 
overall) and decreased further in the OLE to less than 1% of patients. Good long-term 
skin tolerability means patients are unlikely to discontinue treatment with rivastigmine 
patch owing to skin reactions. 
Previous studies have pointed to an association between GI AEs, such as nausea, 
vomiting, and diarrhea, and ChEI dose.19 In a 28-week OLE to the 24-week IDEAL 
(Investigation of transDermal Exelon in ALzheimer’s disease) trial, the incidence of GI 
AEs with 9.5 mg/24 h patch was greater in those patients who previously received 
placebo during the DB phase compared with those who had received rivastigmine (9.5 
mg/24 h patch, 17.4 mg/24 h patch or 12 mg/day capsules).20 This led to the 
recommendation that the rivastigmine patch dose be increased in a 4-week step-wise 
manner, starting on the low-dose 4.6 mg/24 h rivastigmine patch for a minimum of 4 
weeks before increasing to 9.5 mg/24 h rivastigmine patch.5, 20 In the DB OPTIMA trial, 
GI AEs were more frequently reported in patients up-titrated from 9.5 mg/24 h to 13.3 
mg/24 h patch than for patients continuing on 9.5 mg/24 h patch.8 Likewise, in the DB 
ACTION study the incidence of GI AEs was higher in patients receiving 13.3 mg/24 h 
compared with 4.6 mg/24 h patch (nausea: 6.2% versus 2.8%; vomiting 7.0% versus 
2.5%; diarrhea: 6.5% versus 5.3%, respectively).9 It is also now recommended that 
patients receive 9.5 mg/24 h patch for a minimum of 4 weeks before up-titrating to the 
13.3 mg/24 h patch dose.5  
In the ACTION study OLE, the frequency of GI AEs was lower in those patients who 
continued on 13.3 mg/24 h patch than those who switched from 4.6 mg/24 h to 13.3 
mg/24 h patch (nausea: 1.5% versus 4.0%; vomiting 3.0% versus 8.0%; diarrhea: 2.5% 
versus 5.0%, respectively). These safety data support previous findings that GI AEs 
are associated with initial rivastigmine dose increase.8, 20 Once patients are established 
on the high dose, GI AE frequency decreases, suggesting that patient tolerability of 
14 
 
13.3 mg/24 h rivastigmine patch improves with time. Further supporting this, the 
reported incidence of overall AEs was lower for patients continuing on 13.3 mg/24 h in 
the 24-week OLE than those randomized to 13.3 mg/24 h in the first 24 weeks of 
rivastigmine patch treatment (DB phase) (57.9% versus 74.6%, respectively).9 The 48-
week DB OPTIMA trial of patients with mild-to-moderate AD declining on 9.5 mg/24 h 
rivastigmine patch, who were randomized either to continue on 9.5 mg/24 h patch or 
up-titrate to 13.3 mg/24 h patch, reported a similar decline in AEs with time (Week 0–
24, 64.6% and 54.8%; Week 24–28, 42.3% and 40.2%, 13.3 mg/24 h and 9.5 mg/24 h, 
respectively).8 In light of these findings, patients with poor tolerability of 13.3 mg/24 h 
patch who have down-titrated to a lower maintenance dose may later show improved 
tolerability to the high-dose patch after a more prolonged exposure to lower-dose 
rivastigmine patch treatment.  
The OLE collected efficacy data for long-term 13.3 mg/24 h rivastigmine patch 
treatment, in addition to assessing safety and tolerability. An important objective of 
treatment when managing a patient with severe AD is achieving stabilization of, or 
reducing decline in, cognitive function and the ability to perform ADL. As expected, 
given the advanced disease stage of the population under study,21 at 48 weeks 
patients in both treatment groups showed decline in cognitive ability (SIB) and their 
ability to perform ADL (ADCS-ADL-SIV). However, numerically less decline was 
observed in those who continued on 13.3 mg/24 h patch long term compared with 
those patients who up-titrated from 4.6 mg/24 h to 13.3 mg/24 h patch at the start of 
the OLE. At the end of the DB study (Week 24), patients receiving 4.6 mg/24 h 
rivastigmine patch already showed significantly greater decline in cognitive and 
functional ability compared with patients randomized to 13.3 mg/24 h rivastigmine 
patch.9 The effect of temporary down-titration to 9.5 mg/24 h patch in the 13.3 mg/24 h 
patch group for the first four weeks of the OLE on the study findings is unknown, but it 
may have increased the rate of decline in this treatment arm. However, overall, the 
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extension data confirm the superior symptomatic efficacy of 13.3 mg/24 h compared 
with 4.6 mg/24 h rivastigmine patch: patients with delayed switching to 13.3 mg/24 h 
patch do not ‘catch-up’ in the longer-term. These observations suggest that early and 
sustained intervention with 13.3 mg/24 h rivastigmine patch is needed to achieve a 
maximum delay in symptomatic progression in patients with severe AD. 
There were no marked differences in the distribution of ADCS-CGIC ratings between 
treatment groups, suggesting the global function of patients was similar in those who 
continued on 13.3 mg/24 h patch for the duration of the study, and those who up-
titrated to 13.3 mg/24 h patch. At the end of the DB phase, a significantly higher 
percentage of patients displayed improvement in clinical status when receiving 13.3 
mg/24 h rivastigmine patch compared with 4.6 mg/24 h (P = 0.0094). However, caution 
should be exercised when drawing comparisons between the OLE and the initial DB 
study owing to differences in study design. Limitations of this extension study include 
its open-label nature, and that it was not powered for statistical analysis between 
treatment groups on this, or any other outcome measure, hence between-group 
comparisons are based on numerical differences. In terms of blinding, between-group 
measurements are unlikely to be affected by open-label status, as prior DB 
randomization was not revealed to OLE participants. Regarding overall efficacy, the 
severity of AD in the study population is likely to mitigate any patient-bias in 
assessments.  
As this was the first trial of rivastigmine patch treatment in patients with severe AD, the 
4.6 mg/24 h dose was selected as a low-dose active comparator to fully evaluate the 
efficacy of high-dose rivastigmine. Using 4.6 mg/24 h rivastigmine patch as a 
comparator in this study may mask the true treatment effect of rivastigmine patch 
compared with placebo. However, for patients with AD, 9.5 mg/24 h rivastigmine patch 
is currently the minimum effective dose. It would be interesting to compare these 
findings with patients who up-titrate to 13.3 mg/24 h from 9.5 mg/24 h rivastigmine 
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patch straight away (after a 4-week step-wise dose increase, as performed in the OLE) 
compared with delaying up-titration to 13.3 mg/24 h, as a more accurate reflection of 
the real-world clinical setting. 
Previous studies report that transdermal delivery is the preferred route of administration 
by caregivers of patients with AD, compared with capsules, and greater satisfaction 
with rivastigmine patch is associated with higher rates of adherence.22-24 In practical 
terms, transdermal delivery has a number of advantages over oral capsules for patients 
with AD and their caregivers; the patch acts as a visual reminder that medication has 
been taken;25 patch administration is easier, particularly in patients who are confused 
or display behavioral problems;25 patch delivery is well-suited for patients who have 
difficulty swallowing. Although caregiver preference for transdermal versus oral 
formulations has not been confirmed in a sub-population of patients with severe AD, it 
is anticipated that the simple treatment regimen offered by a transdermal patch would 
also appeal to caregivers of patients with more advanced disease.  
Conclusion 
In summary, no clinically relevant differences were observed in safety and tolerability 
between patients switched from the 4.6 mg/24 h to 13.3 mg/24 h rivastigmine patch 
and those who continued long-term treatment with the high-dose patch in the OLE 
study. Safety results appeared to be broadly consistent with those previously reported 
with the 13.3 mg/24 h patch in patients with mild-to-moderate AD,8 with tolerability 
improving with time on rivastigmine treatment. Greater, but more variable, decline in 
cognitive function and on the ability to perform ADL was observed in patients switched 
from 4.6 mg/24 h to 13.3 mg/24 h patch at the start of the OLE, compared with those 
patients who continued on 13.3 mg/24 h patch long term. Early and sustained 
administration of 13.3 mg/24 h rivastigmine patch may provide clinically relevant 
benefits for patients with severe AD.  
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Figure legends 
 
Figure 1: Patient disposition throughout the study by DB treatment group.  
AEs, adverse events; DB, double-blind; N, number of patients in the population; n, 
number of patients; OLE, open-label extension. †One patient was randomized but was 
not exposed to study medication.  
 
Figure 2: Change from baseline to Week 48 on (A) SIB score and (B) ADCS-ADL-SIV, 
and (C) categorical analysis of change in score at Week 48 on the ADCS-CGIC 
(MFAS–LOCF).  
 
ADCS-ADL-SIV, Alzheimer’s Disease Cooperative Study–Activities of Daily Living 
scale–Severe Impairment Version; ADCS-CGIC, Alzheimer’s Disease Cooperative 
Study–Clinical Global Impression of Change; LOCF, last observation carried forward; 
MFAS, modified full analysis set; OLE, open-label extension; SEM, standard error of 
the mean; SIB, Severe Impairment Battery. Error bars represent the SEM. *P < 0.05 
13.3 mg/24 h versus 4.6 mg/24 h patch; **P < 0.0001 13.3 mg/24 h versus 4.6 mg/24 h 
patch. For the SIB, 13.3 mg/24 h patch, n = 183–185 and 4.6 mg/24 h patch, n = 192–
194. For the ADCS-ADL-SIV, 13.3 mg/24 h patch, n = 182–183 and 4.6 mg/24 h patch, 
n = 187–189. 
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Table 1: Patient demographics and background characteristics by treatment group 
(safety set) 
 Rivastigmine Patch  
Demographic or 
characteristic 
13.3 mg/24 h 
(N = 197) 
4.6 mg/24 h 
(N = 199) 
Overall 
(N = 396) 
Age, years 
Mean (SD) 
 
78.0 (8.3) 
 
76.1 (9.1) 
 
77.1 (8.8) 
Gender, % 
Female 
 
63.5 
 
68.3 
 
65.9 
Race, % 
Caucasian 
Black 
Other 
 
83.2 
9.1 
7.6 
 
85.9 
7.0 
7.0 
 
84.6 
8.1 
7.3 
MMSE at screening 
Mean (SD) 
Range 
 
9.15 (2.7) 
3.0–13.0 
 
9.19 (2.9) 
3.0–19.0 
 
9.17 (2.8) 
3.0–19.0 
Years since diagnosis of AD 
Mean (SD) 4.28 (2.7) 3.73 (2.4) 4.00 (2.6) 
Years since diagnosis of severe dementia 
Mean (SD) 1.09 (1.8) 1.05 (1.5) 1.07 (1.7) 
Living situation, % 
Home 
Assisted-living facility 
Other 
 
90.4 
7.6 
2.0 
 
89.4 
8.5 
2.0 
 
89.9 
8.1 
2.0 
AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; N, number of patients 
in the population; SD, standard deviation.  
Table 2: Most frequent adverse events† in the OLE study (safety set).  
 
 
AEs, n (%) 
Rivastigmine patch 
13.3 mg/24 h 
(N = 197) 
4.6 mg/24 h 
(N = 199) 
Patients with ≥1 AE 114 (57.9) 119 (59.8) 
Urinary tract infection 22 (11.2) 21 (10.6) 
Weight decreased 15 (7.6) 15 (7.5) 
Fall 9 (4.6) 12 (6.0) 
Agitation 9 (4.6) 11 (5.5) 
Vomiting 6 (3.0) 16 (8.0) 
Diarrhea 5 (2.5) 10 (5.0) 
AEs, adverse events; N, number of patients in the population; n, number of patients 
reporting AE; OLE, open-label extension. †AEs occurring in ≥5.0% of patients in either 
treatment group are shown. A patient with multiple occurrences of an AE was counted 
only once in the AE category. AEs are presented by descending frequency in the 13.3 
mg/24 h patch group. 
Table 3: Incidence of SAEs, deaths and discontinuations due to AEs and SAEs (safety 
set).  
 
 
 
Rivastigmine patch 
13.3 mg/24 h 
(N = 197) 
n (%) 
4.6 mg/24 h 
(N = 199) 
n (%) 
SAEs 32 (16.2) 32 (16.1) 
Deaths 4 (2.0) 0 (0.0) 
Discontinued due to SAEs 14 (7.1) 10 (5.0) 
Discontinued due to non-serious SAEs 9 (4.6) 15 (7.5) 
Discontinued due to gastrointestinal AEs 2 (1.0) 6 (3.0) 
Discontinued due to application site 
irritations 
2 (1.0) 1 (0.5) 
AEs, adverse events; N, number of patients in the population; n, number of patients 
reporting SAE, death or discontinuation; SAE, serious adverse event.    
 
 
